小儿健脾补肺膏方对儿童反复呼吸道感染的疗效及其免疫机制

 为探讨小儿健脾补肺膏方治疗儿童反复呼吸道感染（RRTI）的疗效及对患儿免疫功能的影响，将2019年1月至2020年12月佛山复星禅诚医院收治的RRTI患儿随机分为中西医组（小儿健脾补肺膏方+免疫活性肽）与对照组（免疫活性肽），指标包括外周血CD3+、CD4+和CD8+流式细胞检测、最大呼气流量（PEF）及RRTI中医证候评分，随访至治疗后1年。结果显示，治疗后中西医组的CD3+和CD4+水平、PEF、RRTI中医证候评分均显著高于对照组，中西医组治疗期间的不良反应（2.22%）低于对照组（13.33%），而临床有效率（97.77%）高于对照组（84.44%）；说明小儿健脾补肺膏方+免疫活性肽治疗儿童RRTI的中西医结合方案可进一步提高患儿的免疫水平，具有改善呼气功能、临床症状的优势，有利于提高安全性及临床疗效。

Therapeutic effect of Xiaoer Jianpi Bufei ointment on recurrent respiratory tract infection in children and its immune mechanism

In order to identify the efficacy of Xiaoer Jianpi Bufei ointment on the treatment of recurrent respiratory tract infection (RRTI) in children and its potential immunology mechanism, children with RRTI admitted to Foshan Fuxing Chancheng hospital from Jan 2019 to Dec 2020 were randomly divided into the combination group of traditional Chinese medicine (TCM) and western medicine (Xiaoer Jianpi Bufei ointment + immunoactive peptide) and control group (immunoactive peptide). Indicators included: the peripheral blood CD3+, CD4+ and CD8+ detected by flow cytometry, maximum expiratory flow (PEF), and TCM syndrome score for RRTI. Subjects were followed up to 1 year after the treatment. The results showed that after the treatment, the levels of CD3+ and CD4+ , PEF, RRTI and TCM syndrome scores of the combination group were significantly higher than those of the control group. During the treatment, the adverse reactions (2.22%) of the combination group were lower than those of the control group (13.33%), and finally the efficacy of the combination group (97.77%) was higher than that of the control group (84.44%). It suggests that the integrated Chinese and western medicines of Xiaoer Jianpi Bufei ointment combined with immunoactive peptide for treatment of children's RRTI can further improve the immune level and expiratory function, and relieve the clinical symptoms, which may improve the clinical safety and efficacy.